Cite
Effect of the addition of rituximab to salvage chemotherapy prior to autologous stem cell transplant in aggressive CD20+ lymphoma: a cohort comparison from the NCIC Clinical Trials Group Study LY.12.
MLA
Baetz, Tara, et al. “Effect of the Addition of Rituximab to Salvage Chemotherapy Prior to Autologous Stem Cell Transplant in Aggressive CD20+ Lymphoma: A Cohort Comparison from the NCIC Clinical Trials Group Study LY.12.” Leukemia & Lymphoma, vol. 58, no. 1, Jan. 2017, pp. 64–69. EBSCOhost, https://doi.org/10.1080/10428194.2016.1187274.
APA
Baetz, T., Chen, B. E., Couban, S., Tom Kouroukis, C., Buckstein, R., Kuruvilla, J., Howson-Jan, K., Szwajcer, D., Federico, M., Meyer, R. M., Djurfeldt, M. S., Hay, A. E., Shepherd, L., & Crump, M. (2017). Effect of the addition of rituximab to salvage chemotherapy prior to autologous stem cell transplant in aggressive CD20+ lymphoma: a cohort comparison from the NCIC Clinical Trials Group Study LY.12. Leukemia & Lymphoma, 58(1), 64–69. https://doi.org/10.1080/10428194.2016.1187274
Chicago
Baetz, Tara, Bingshu E. Chen, Stephen Couban, C. Tom Kouroukis, Rena Buckstein, John Kuruvilla, Kang Howson-Jan, et al. 2017. “Effect of the Addition of Rituximab to Salvage Chemotherapy Prior to Autologous Stem Cell Transplant in Aggressive CD20+ Lymphoma: A Cohort Comparison from the NCIC Clinical Trials Group Study LY.12.” Leukemia & Lymphoma 58 (1): 64–69. doi:10.1080/10428194.2016.1187274.